Antibody-drug conjugates, or ADCs, are manufactured antibodies that are administered to patients intravenously designed to deliver drugs to tumors. "Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio," at 0753 GMT, incorrectly said that ADCs are designed to use the body's own antibodies to deliver drugs to tumors.

(END) Dow Jones Newswires

04-03-24 0904ET